Adenosine, lidocaine and Mg²⁺ (ALM)fluid therapy attenuates systemic inflammation, platelet dysfunction and coagulopathy after non-compressible truncal hemorrhage by Letson, Hayley & Dobson, Geoffrey
RESEARCH ARTICLE
Adenosine, lidocaine and Mg2+ (ALM) fluid
therapy attenuates systemic inflammation,
platelet dysfunction and coagulopathy after
non-compressible truncal hemorrhage
Hayley Letson☯, Geoffrey Dobson☯*
Heart, Trauma and Sepsis Research Laboratory, College of Medicine and Dentistry, James Cook University,
Townsville, Queensland, Australia
☯ These authors contributed equally to this work.
* geoffrey.dobson@jcu.edu.au
Abstract
Background
Systemic inflammation and coagulopathy are major drivers of injury progression following
hemorrhagic trauma. Our aim was to examine the effect of small-volume 3% NaCl adeno-
sine, lidocaine and Mg2+ (ALM) bolus and 0.9% NaCl/ALM ‘drip’ on inflammation and coagu-
lation in a rat model of hemorrhagic shock.
Methods
Sprague-Dawley rats (429±4 g) were randomly assigned to: 1) shams, 2) no-treatment, 3)
saline-controls, 4) ALM-therapy, and 5) Hextend®. Hemorrhage was induced in anesthe-
tized-ventilated animals by liver resection (60% left lateral lobe and 50% medial lobe). After
15 min, a bolus of 3% NaCl ± ALM (0.7 ml/kg) was administered intravenously (Phase 1) fol-
lowed 60 min later by 4 hour infusion of 0.9% NaCl ± ALM (0.5 ml/kg/hour) with 1-hour moni-
toring (Phase 2). Plasma cytokines were measured on Magpix® and coagulation using
Stago/Rotational Thromboelastometry.
Results
After Phase 1, saline-controls, no-treatment and Hextend® groups showed significant falls
in white and red cells, hemoglobin and hematocrit (up to 30%), whereas ALM animals had
similar values to shams (9–15% losses). After Phase 2, these deficits in non-ALM groups
were accompanied by profound systemic inflammation. In contrast, after Phase 1 ALM-
treated animals had undetectable plasma levels of IL-1α and IL-1β, and IL-2, IL-6 and TNF-
αwere below baseline, and after Phase 2 they were less or similar to shams. Non-ALM
groups (except shams) also lost their ability to aggregate platelets, had lower plasma fibrino-
gen levels, and were hypocoagulable. ALM-treated animals had 50-fold higher ADP-
induced platelet aggregation, and 9.3-times higher collagen-induced aggregation compared
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to saline-controls, and had little or no coagulopathy with significantly higher fibrinogen shift-
ing towards baseline. Hextend® had poor outcomes.
Conclusions
Small-volume ALM bolus/drip mounted a frontline defense against non-compressible trau-
matic hemorrhage by defending immune cell numbers, suppressing systemic inflammation,
improving platelet aggregation and correcting coagulopathy. Saline-controls were equiva-
lent to no-treatment. Possible mechanisms of ALM’s immune-bolstering effect are
discussed.
Introduction
Non-compressible torso hemorrhage is the leading cause of potentially preventable death in
military and civilian trauma [1–4]. The majority of military deaths occur from hypovolemic-
induced cardiovascular collapse in far-forward environments [1], or in civilian settings within
24 hours after injury [5, 6]. Late mortality is often due to activation of an early and excessive
systemic inflammatory response, and a triad of complicating factors involving coagulopathy
with conspicuous fibrinolysis, acidosis and hypothermia [7–10]. Early traumatic-induced coa-
gulopathy is frequently a bleeding or oozing phenotype, which can evolve over time into a
spectrum of clinical states ranging from a worsening systemic hypocoagulopathy [11] to fibri-
nolysis shutdown [12]. Three key targets of early resuscitation are to: 1) reduce bleeding and
fibrinolysis, 2) "rescue and reset" the cardiovascular system, and 3) restore endothelial health.
Restoring endothelial health is vital because it is the master controller of inflammation, coagu-
lation, oxygen supply, vascular reactivity and lymphatic function [13, 14]. Currently, there is
no fluid that successfully targets these three pillars of resuscitation.
Since 2008 we have been developing a small-volume fluid therapy comprising a bolus of
7.5% or 3% NaCl with adenosine, lidocaine and Mg2+ (ALM) bolus for resuscitation and a
0.9% NaCl ALM ‘drip’ for continuum-of-care [15]. The original idea for combining A, L and
M came from developing a new ‘polarizing’ cardioplegia, which is in clinical use [16]. At high
(0.25 to 1 mM) concentrations, ALM arrests the heart, and at lower ‘non-arrest’ concentrations
(10-fold less), it resuscitates the heart. The ’non-arrest’ ALM bolus and infusion ’drip’ treat-
ments have been shown to protect rat and pig models against regional myocardial ischemia,
lethal arrhythmias, cardiac arrest, hemorrhagic shock, endotoxemia, infection and sepsis [15,
17–19]. A, L and M alone do not confer these benefits [15]. In 2016, we showed that the ALM
therapy significantly increased survival, improved cardiac function, and reduced internal
blood loss by up to 60% in the rat model of hepatic hemorrhage and shock [20]. ALM also cor-
rects early coagulopathy in a number of rat models [11, 15, 18, 21, 22]. The aim of the present
study was to examine the effect of small-volume 3% NaCl ALM bolus and 4 hours 0.9% NaCl
ALM ‘drip’ on inflammation, hematopoietic-immune and coagulation responses in a rat
model of hepatic hemorrhage and shock. We hypothesize ALM therapy will blunt inflamma-
tion, decrease immune activation, and correct coagulopathy with preserved platelet function
following uncontrolled bleeding in the rat.
ALM therapy suppresses systemic inflammation
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Methods
Animals and ethics
Male Sprague-Dawley rats (429±4 g) were obtained from James Cook University’s Breeding
Colony, Townsville, Australia. All animals were housed in a 14–10 hr light-dark cycle with free
access to food and water ad libitum, and were anesthetized intraperitoneally with 100 mg/kg
sodium thiopentone (Thiobarb; Lyppard, Townsville, Australia). Anesthesia was administered
as required throughout the protocol, and depth of anesthesia was monitored via pedal reflex.
The study conforms to the Guide for Care and Use of Laboratory Animals (NIH, 8th Edition,
2011) and was approved by James Cook University Animal Ethics Committee (A2118) and US
Animal Care and Review Use Office (ACURO). The study was classified as “unconscious with-
out recovery” meaning that any animal death resulting from the different treatments was
under anesthesia with no adverse impact on the animal. Animals that survived to end the
study (6 hr 15 min after liver resection) were euthanized with Lethabarb (Pentobarbitone
sodium, 325 mg/ml).
Surgical protocol
The surgical protocol has been described previously by Letson and Dobson [20]. Briefly, fol-
lowing anesthesia, a tracheotomy was performed and animals ventilated on humidified room
air. The left femoral vein and artery were cannulated for infusions and hemodynamic monitor-
ing (Powerlab, ADInstruments) [23], and the right femoral artery was cannulated for blood
sampling [24]. Following surgical instrumentation, anesthetized animals had a 30-min baseline
equilibration period (Fig 1). An additional 8 male Sprague-Dawley rats were anesthetized, ven-
tilated, and had cannulation of the left femoral artery to obtain a 2.5 ml blood sample for base-
line measurements of plasma cytokines, ROTEM coagulation analysis, and PT, aPTT and
fibrinogen (see below) before humane euthanasia with Lethabarb (Pentobarbitone sodium,
325 mg/ml).
Uncontrolled bleeding
Uncontrolled hemorrhage was produced via liver injury with excision of 60% of the left lateral
lobe and 50% of the medial lobe as previously described [20]. A 2-cm transverse laparotomy
exposed the liver for sharp dissection and the cut edges were allowed to bleed freely into the
peritoneal cavity. The laparotomy was quickly closed with running suture.
Experimental design
Fifteen minutes after commencement of hepatic injury, rats were randomly assigned to: 1)
Sham (laparotomy without liver resection/bleed, 2) No-Treatment, 3) Saline controls, 4) ALM
therapy, or 5) Hextend1 (all n = 24) (Fig 1). Any animal that reached MAP<25 mmHg or
recovered MAP>90 mmHg prior to Phase 1 resuscitation was excluded from analysis. For
Phase 1 resuscitation animals received an intravenous bolus as follows: 1) Sham, 0.7 ml/kg 3%
NaCl; 2) No-treatment, no fluid bolus; 3) Saline controls, 0.7 ml/kg 3% NaCl; 4) ALM therapy,
0.7 ml/kg 3% NaCl with 1 mM Adenosine, 3 mM Lidocaine, and 2.5 mM MgSO4; 5) Hex-
tend1 2.5 ml bolus (5.94±0.12 ml/kg) + further 2.5 ml if required to maintain MAP>45
mmHg (Fig 1). Seventy-one percent (17/24) of Hextend1-treated animals required a second
bolus during Phase 1. Sixty minutes after bolus administration, all treatment groups received
4-hr continuous 0.5 ml/kg/hr infusion (Phase 2 resuscitation) as follows: 1) Sham, 0.9% NaCl;
2) No-treatment, no drip; 3) Saline controls, 0.9% NaCl; 4) ALM therapy, 0.9% NaCl ALM (50
mg adenosine, 100 mg lidocaine, 50 mg MgSO4/10 ml); 5) Hextend
1, 0.9% NaCl. Fluids were
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kept at room temperature (~21˚C) and were not warmed prior to infusion. After 4-hr infusion
animals were monitored for 60 min (total experimental time from liver injury was 6 hr 15
min) (Fig 1). Consistency of liver injury was ensured by comparing weight of resected liver
portions with remaining liver weight. Resected liver weight was 25±0.4% of total liver weight
with no significant differences between groups. In order to obtain sufficient blood for mea-
surement of all endpoints, each treatment group had to be repeated three times (n = 24 per
treatment) (Fig 1).
Complete blood counts
The VetScan HM5 Hematology system (REM Systems, Macquarie Park, New South Wales)
was used for red cell, hemoglobin, hematocrit, white blood cell, and platelet counts at baseline,
60 min phase 1 resuscitation, and 240 min and 300 min phase 2 resuscitation.
Plasma cytokine analysis
Milliplex1 Rat Cytokine/Chemokine Magnetic Bead Panel (Lot #: 2647883, Abacus ALS, Mea-
dowbrook, Queensland) was used to measure plasma levels of GM-CSF, IL-1α, IL-2, IL-12/
p70, IL-4, RANTES, IL-1β, TNFα, IL-6, IL-10, and IFNγ, on Magpix1 (Luminex Corporation,
Austin, Texas, USA). Assay was carried out according to manufacturer’s instructions. Detec-
tion ranges were as follows: GM-CSF, IL-1α, IL-2, IL-12/p70: 4.9–50,000 pg/ml; IL-4,
RANTES: 4.9–20,000 pg/ml; IL-1β, TNFα: 2.4–10,000 pg/ml; IL-6: 73.2–300,000 pg/ml; IL-10:
7.3–30,000 pg/ml; IFNγ: 14.6–60,000 pg/ml. Assay sensitivities (minimum detectable concen-
tration, pg/ml), intra-assay precision (%CV), and inter-assay precision (%CV) for each analyte
were GM-CSF: 6.8, 2.2, 7.4; IL-1α: 4.2, 2.2, 4.8; IL-2: 5.4, 3.2, 13.3; IL-12/p70: 3.3; 2.2, 7.8; IL-4:
3.1, 3.1, 10.7; RANTES: 1.3, 6.3, 17.1; IL-1β: 2.8, 3.6, 11.3; TNFα: 1.9, 2.7, 10.8; IL-6: 30.7, 2.3,
12.7; IL-10: 2.7, 3.8, 9.0; IFNγ: 6.2, 2.7, 12.4.
Platelet aggregation tests
Platelet function was assessed in platelet-rich plasma (PRP) using the PAP-8e Platelet Aggrega-
tion Profiler and agonists ADP (BioData adenosine-5’-diphosphate reagent, 2 x 10−4) and
Fig 1. Schematic of the in vivo rat model of truncal bleeding and shock treated with two-phase
resuscitation therapy. Animals were anesthetized and mechanically ventilated for the entire experimental
and monitoring period (~7 hr 15 min). Body temperature was allowed to drift after anesthesia.
https://doi.org/10.1371/journal.pone.0188144.g001
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Collagen (BioData soluble calf skin collagen, 1.9 mg/ml). PRP was prepared using a standard-
ized technique of double centrifugation [25].
Coagulation status
Stago Analysis: Prothrombin time (PT, sec), activated partial thromboplastin time (aPTT, sec),
and fibrinogen (g/dL) were measured on the STA Compact (Diagnostica Stago, Doncaster,
Australia) using reagents STA Neoplastine Cl (rabbit brain), Triniclot aPTT HS, and STA Liq-
uid Fib. Rotational Thromboelastometry (ROTEM1): ROTEM1 (Tem International, Munich,
Germany) was conducted according to manufacturer’s instructions with all kinetic, elongation
and lysis parameters defined in Letson and Dobson [22, 26]. Quality control measurements
(ROTROL-N and ROTROL-P) were performed weekly.
Statistical analysis
A priori power analysis to determine sample sizes was conducted using G-power3 program to
minimize Type 1 errors (MAP 60 min phase 1 resuscitation; n = 8). SPSS Statistical Package 22
was used for all statistical analysis (IBM, St Leonards, New South Wales). All values are
expressed as mean ± SEM. Data normality was assessed numerically with Shapiro-Wilks, and
Levene’s test was used to determine equality of variances. Parametric data were evaluated
using analysis of variance (ANOVA) followed by Tukey’s Honestly Significant Difference or
Dunnet’s post-hoc test. Two-way ANOVA comparison was used for within group compari-
sons. Longitudinal data was analyzed using General Linear Model Repeated Measures
ANOVA with Greenhouse-Geisser correction if Mauchy’s Test of Sphericity was not met.
Non-parametric data was evaluated using Kruskal-Wallis followed by Dunn’s test. Multiplex
cytokine assays were analyzed using MILLIPLEX Analyst 5.1 software (Luminex Corporation,
Austin, Texas, USA). Statistical significance was defined as p<0.05.
Results
Hemoglobin, hematocrit, red cell counts
In shams (no bleed with saline bolus/drip) there was no change in hemoglobin levels but there
was a significant fall in red blood cell count (RBC) and hematocrit (HCT) during Phase 1
resuscitation compared to baseline (Table 1). Further falls in red blood cell count and HCT
occurred after Phase 2 but these were not significant. In the no-treatment group, hemoglobin,
RBC and HCT all significantly fell by 10–14% after Phase 1 and 20–23% after Phase 2. In saline
controls, the hematological parameters changed similar to the no-treatment group (Table 1).
In contrast, the ALM group had hematological parameters similar to shams after Phase 1 and
2. In both shams and ALM group, RBC, hemoglobin and HCT increased towards baseline
after infusion was switched off (see Table 1). Hextend1 had significant falls in all parameters
over Phase 1 and Phase 2 resuscitation with nearly 30% falls in RBC, hemoglobin and HCT
(Table 1).
Differential white blood cell counts
In shams, total white cell count and monocytes were not significantly different throughout the
experiment (Table 1). In contrast, lymphocyte counts progressively decreased by 40%, 52%
and 61% after Phase 1, 2 and monitoring (p<0.05), and neutrophils increased by 2.1 to 2.4
times. These opposing changes in lymphocyte and neutrophil counts were also found when
expressed as a percentage of total white cells (Table 1). No-treatment animals experienced a set
of complex changes with a significant decrease in total white cell count after Phase 1 (9%) then
ALM therapy suppresses systemic inflammation
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Table 1. Red cell parameters and differential white blood cell counts at baseline, Phase 1 and Phase 2 resuscitation or at the time of death**, and
after 60 min monitoring period (end of experiment) in shams, untreated animals, saline controls, ALM therapy group, and Hextend® group.
Group Resuscitationor Survival Time
(min)
HgB (g/L) HCT (%) RBC
(1012/L)
WBC
(109/L)
LYM
(109/L)
NEU
(109/L)
MON
(109/L)
LYM (%) NEU (%) MON (%)
Sham Baseline 15.5±0.4 37.7±0.6 7.32±0.09 10.7±1.3 7.6±0.8 2.4±0.4 0.7±0.2 72.8±2.9 21.4±1.7 5.9±1.4
Phase 1 14.7±0.5 34.7
±1.3¥
6.76±0.18¥ 10.9±1.1 4.6±0.7¥ 5.7±0.4¥ 0.6±0.1 40.2
±3.8¥
53.9
±4.0¥
5.9±0.4
Phase 2 14.3±1.1 33.7±2.3 6.39±0.46 9.7±2.7 3.6±1.0¥ 5.1±1.5 1.0±0.3 37.9
±3.0¥
52.6
±2.6¥
9.5±1.3‡
Monitoring 15.4±0.9 35.9±1.8 7.06±0.43 9.4±1.7 3.0±0.7¥ 5.6±1.01 0.8±0.2 30.6
±3.8‡
60.8
±4.0¥
8.6±1.1
No
Treatment
Baseline 14.1±0.5 36.6±2.4 7.00±0.46 8.0±1.1 5.8±0.8 1.7±0.3 0.5±0.1 72.2±2.6 20.8±1.6 7.0±1.4
Phase 1 12.7±0.4* 30.9
±1.2^
5.88±0.22* 7.3±0.9* 3.2±0.6¥ 3.6±0.7#¥ 0.5±0.1 45.3
±6.9¥
48.4
±6.4¥
6.3±1.2
117±13 10.8±1.0*¥ 29.8±5.3 5.61±1.07 16.6±2.1‡ 5.3±0.9§ 9.6±1.3‡ 1.7±0.2‡ 32.0
±3.4¥
57.8
±3.6¥
10.2
±0.6§
Monitoring (no
survivors)
Saline
Control
Baseline 14.3±0.9 35.2±1.1 6.80±0.24 7.9±1.7 6.1±1.2¥ 1.4±0.5 0.4±0.1 81.8±2.8 14.0±2.6 4.3±0.4
Phase 1 12.6±0.7* 31.0
±1.8^
5.78±0.30* 5.6±0.9* 3.1±0.5 2.3±0.6* 0.3±0.1# 56.8
±4.7#¥
38.4
±4.5#¥
4.7±0.4
298±49 12.0±1.1 28.2±2.5 5.11±0.45¥ 14.1±2.5§ 5.4±0.9 7.3±1.5‡ 1.4±0.3‡ 40.4
±2.7‡
49.9
±2.8¥
9.6±1.1‡
Monitoring (one survivor) 16.5 37.3 7.19 5.30 1.64 3.30 0.35 31.0 62.3 6.7
ALM
Therapy
Baseline 15.5±0.4 39.9±0.5 7.47±0.17 11.3±0.9 8.2±0.6 2.3±0.3 0.8±0.1 73.3±2.7 19.8±2.4 7.0±0.9
Phase 1 14.4±0.3 36.0±1.3 6.79±0.27 10.0±1.2 4.9±0.5¥ 4.6±0.7¥ 0.5±0.1 45.0
±5.6¥
44.5
±2.8¥
4.6±0.4¥
Phase 2 13.9±0.9 35.1
±1.5¥
6.63±0.36 8.6±1.9 3.1±0.6¥ 4.7±1.1 0.7±0.2 38.2
±2.1¥
52.9
±2.2¥
8.9±1.3§
Monitoring 15.2±0.8 38.0±1.3 7.44±0.23 10.6±2.3 4.0±1.1 5.4±0.9 1.2±0.3 36.9
±2.8‡
52.5
±4.0¥
10.6
±1.31
Hextend® Baseline 14.7±0.8 35.4±1.9 6.74±0.33 8.7±1.0 6.6±0.5 1.6±0.3 0.6±0.2 77.4±2.5 16.7±1.8 5.9±1.1
Phase 1 12.0±0.6*¥ 29.3
±1.5*¥
5.49
±0.29*¥
5.1±0.5*¥ 3.7±0.4¥ 1.2±0.3† 0.2±0.0† 72.9
±3.0¶
22.3
±3.4¶
4.8±0.7
82±42 10.8±0.5*‡ 25.8
±1.0‡
4.84±0.18‡ 14.4±4.0§ 6.3±1.5 6.8±2.1§ 1.4±0.5 49.3
±4.6†‡
41.7
±4.1†‡
9.1±0.8§
Monitoring (no
survivors)
Data represent mean ± standard error of the mean. HgB = hemoglobin; HCT = hematocrit; RBC = red blood cells; WBC = white blood cells;
LYM = lymphocytes; NEU = neutrophils; MON = monocytes. LYM, MON, and NEU are presented as absolute values and percentage of total white blood cell
count. n = 8 except as indicated for 60 min monitoring period after Phase 2 resuscitation due to early mortality.
** Mean survival times are from Letson and Dobson (2017).
*p<0.05 compared to Sham and ALM;
^p<0.05 compared to ALM;
#p<0.05 compared to Sham;
†p<0.05 compared to Sham, No Treatment, and ALM;
¶p<0.05 compared to all groups;
‡p<0.05 compared to baseline and Phase 1 resuscitation;
§p<0.05 compared to Phase 1 resuscitation;
¥p<0.05 compared to baseline;
1p<0.05 compared to Phase 2 resuscitation.
https://doi.org/10.1371/journal.pone.0188144.t001
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a twofold increase after Phase 2 (Table 1). The 9% decrease in white cells was associated with a
45% fall in lymphocytes, no change in monocytes, and a 2.1-fold increase in neutrophils. After
Phase 2, lymphocyte numbers returned to baseline, monocytes increased 3.4 times (p<0.05),
and neutrophils increased 5.6 times (p<0.05) compared to their respective baseline values
(Table 1).
In saline controls, white cell counts underwent similar changes to the no-treatment group.
Total white cells significantly decreased at Phase 1 (29%; p<0.05) and then increased 1.8 times
after Phase 2. Lymphocytes also decreased then rebounded, and monocyte numbers were
unchanged after Phase 1 and increased 3.5-times after Phase 2. In contrast to all other cells,
neutrophils progressively increased 1.6 to 5.2-fold at Phases 1 and 2 (Table 1). At the end of
the experiment, total white cell numbers in saline controls decreased by 33%, lymphocytes
decreased by 73%, monocytes decreased by 13%, and neutrophils increased 2.4-fold compared
to their respective baseline values. In contrast, ALM-treated animals experienced no change in
total white cell counts throughout the experiment, and the differentials changed in magnitude
and direction similar to shams (Table 1). Hextend1 treatment led to changes similar to no
treatment and saline controls.
Systemic inflammation
In shams, most of the plasma cytokines and chemokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-12,
RANTES, GM-CSF and IFN-γ) changed little from baseline after Phase 1 (Table 2). Despite
TNF-α increasing 2.9-fold and IL-10 increasing 7-fold they were not significantly different
from baseline. However, at the end of Phase 2, increases in sham IL-1β (>188-fold), IL-2
(3.3-fold) and IL-6 (109-fold) were significant, and IL-12 was significantly lower (44% lower)
relative to baseline (Table 2). Sham IL-1α increased 62-fold and RANTES around 20-fold
above baseline but these changes were not significantly different. In contrast to shams, no-
treatment had significantly higher IL-1α and β, IL-10 and IFN-γ after Phase 1, and IL-12 sig-
nificantly decreased by 56%. After Phase 2 only one no-treatment animal survived, and it had
high IL-6 (19,278 pg/ml) similar to shams (Table 2).
After Phase 1 resuscitation, saline controls showed similar increases in IL-1α, IL-1β, and
IL-12 levels as no-treatment. However, IL-10 and TNF-α were twofold higher and IL-6 was
63% lower than the no-treatment group. After Phase 2, IL-1α, IL-1β and IL-4 increased 2.1
times, 12.4 times and 3.4 times respectively compared to their Phase 1 values (Table 2). In
addition, RANTES doubled and IFN-γ increased 11.5-fold (18 vs. 208 pg/ml) from Phase 1 to
Phase 2. The greatest change in saline-treated rats occurred in IL-6, which increased 85 times
from Phase 1 to 2 (1324 vs. 110,931 pg/ml). Interestingly, 3% NaCl ALM bolus led to a cyto-
kine profile similar to baseline after Phase 1. That is, IL-1α, IL-1β, and IL-4 were below the
assay’s detection limits, and IL-2, IL-6 and TNF-α were less than baseline (Table 2). After
Phase 2, all cytokines and chemokines were less than shams. Hextend1 treatment at Phase 1
led to similar cytokine levels as no-treatment with the exception of IL-6 and IL-10, which were
83% and 78% less respectively. Other differences were found in RANTES, GM-CSF and IFN-γ,
which were 2–3 times higher than no-treatment.
Coagulation status
Phase 1. Baseline prothrombin time (PT) was 15 sec and increased 2.7-times to 41 and 43
sec for shams and no-treatment after Phase 1 (Fig 2). This increase in PT must be due to the
trauma of surgery, as shams did not have the bleed. PT for saline controls, ALM and Hextend1
groups were 30, 17 and 56 sec respectively (all n = 8) (Fig 2). These clotting times for all groups
were reflected in ROTEM EXTEM and FIBTEM CT with ALM group in EXTEM showing no
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difference from baseline (46 vs. 40 sec) whereas saline controls were 3.4-times ALM (154 vs. 46
sec) and 3.9-times baseline (Table 3). The prolongation of CT indicates hypocoagulopathy in
non-ALM groups (including shams). In saline controls, higher CT was accompanied by slower
clot formation times (319 vs. 35 sec ALM), lower alpha angles (58 vs. 83˚ ALM) and significant
reductions in clot amplitude or strength (A10, MCF) (Table 3). Interestingly, there was little
difference in lysis index between saline and ALM groups (ML = 3–5%). Similar changes were
noted in aPTT and INTEM CT. Baseline aPTT was 35 sec, and increased in shams (144 sec),
no-treatment (79 sec), saline (91 sec) and Hextend1 (132 sec) groups. ALM aPTT was compa-
rable to baseline (39 sec) (Fig 2). Interestingly, in no-treatment rats there was a significant
increase in EXTEM maximum lysis, however, the similar change in APTEM indicates that this
was not hyperfibrinolysis. In summary, saline, no-treatment and Hextend1 groups were all
Table 2. Plasma cytokines and inflammatory markers after Phase 1 and Phase 2 resuscitation in shams, untreated animals, saline controls, ALM
treatment group, and Hextend® group.
Group Resuscitation
Phase
IL-1α
(pg/ml)
IL-1β
(pg/ml)
IL-2
(pg/
ml)
IL-4
(pg/ml)
IL-6 (pg/ml) TNF-α
(pg/ml)
IL-10
(pg/ml)
IL-12
(pg/ml)
RANTES
(pg/ml)
GM-CSF
(pg/ml)
IFN-γ
(pg/ml)
Baseline ND ND 7±3 ND 195±50 14±7 429
±269
59±7 607±103 25±2 ND
Sham Phase 1 2±2 0.1
±0.03
4±1 0.2
±0.2
195±62 40±11 2940
±829
44±11 378±39 35±4 7±3
Phase 2 124±55 188
±70^
23±3^ 10±4 21,200
±9480^
10±1 377±82 33±7^ 1375±351 37±4 44±20
No
Treatment
Phase 1 262
±104
R 115±63R 71±59 7±4 3732±2137R 19±10 1271
±372†
26±4^ 1236±390 38±4 20±51
Phase 2 (n = 1) 14 27 34 ND 19,278 22 1753 32 699 30 21
Saline
Control
Phase 1 205
±132
50±38 8±3# ND 1324±871# 46±11 2811
±556
35±6 869±308* 35±10 18±11
Phase 2 (n = 5) 445
±84
R 618
±85
R 27±51 12±10 110,931
±21,2451
33±6* 2017
±335
R 27±3^ 1818±312
R
43±3 208
±100#
ALM
Therapy
Phase 1 ND ND 2±1 ND 82±27 11±4 1820
±453
24±8 298±86 34±7 3±2
Phase 2 22±19 32±22£ 8±2£ ND 9142±4000 4±1£ 197±82 33±7 638±140 35±5 11±3£
Hextend® Phase 1 297
±65
R 166
±67
R 22±8# 11±5* 633±136
R
15±9 277
±141‡
20±2† 1099±206* 56±7¶ 22±7#
Phase 2 (n = 1) 885 830 62 ND 172,100 38 4259 21 3318 42 255
Data represent mean ± standard error of the mean. ND = Not Detected. Baseline values were obtained from 8 healthy anaesthetized, ventilated rats with
one femoral cut-down to obtain an arterial blood sample (see Methods). Phase 1 measurements were taken after 60 min bolus resuscitation (75 min after
injury). Phase 2 measurements were taken after Phase 1 + Phase 2 resuscitation and one hour monitoring period (375 min after injury). n = 8 unless
indicated. No Treatment and Hextend® groups had only 1 survivor at the end of Phase 2 resuscitation, and there were 5 surviving animals in the Saline
control group.
^p<0.05 compared to Baseline;
R
p<0.05 compared to Baseline, Sham, and ALM;
*p<0.05 compared to Sham and ALM;
#p<0.05 compared to ALM;
1p<0.05 compared to Baseline and ALM;
£ p<0.05 compared to Baseline and Sham;
†p<0.05 compared to Baseline and Saline control;
‡p<0.05 compared to Saline control and No Treatment;
¶p<0.05 compared to all groups.
https://doi.org/10.1371/journal.pone.0188144.t002
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profoundly hypocoagulable with significant reductions in clot strength but without
hyperfibrinolyis.
Phase 2. Due to early mortality there was only n = 3 for no-treatment group, n = 5 for
saline controls and n = 2 for Hextend1 group at Phase 2. PT for shams, no-treatment, saline,
ALM and Hextend1 groups were 94, 23, 165, 41 and 102 sec respectively, and aPTT values
Fig 2. Prothrombin time (sec), activated partial thromboplastin time (sec), and fibrinogen
concentration (g/dL) after Phase 1 (A) and Phase 2 (B) resuscitation at baseline, and in shams, no
treatment, saline controls, ALM therapy, and Hextend® groups. Values represent mean ± SEM. Baseline
values were obtained from 8 healthy anaesthetized, ventilated rats with one femoral cut-down to obtain an
arterial blood sample (see Methods). n = 8 for all groups after Phase 1 resuscitation and Baseline, Sham and
ALM groups at Phase 2 resuscitation. n = 2 for Hextend® group, n = 3 for No treatment group, and n = 5 for
Saline controls at Phase 2 resuscitation due to early mortality. *p<0.05 compared to Baseline and ALM
groups; #p<0.05 compared to Baseline; †p<0.05 compared to ALM group; ¶p<0.05 compared to Baseline,
Sham, and ALM therapy; ‡p<0.05 compared to all groups except No Treatment group.
https://doi.org/10.1371/journal.pone.0188144.g002
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were 130, 64, 177, 100 and 91 sec respectively (Fig 2). In Phase 2, ROTEM confirmed hypocoa-
gulopathy but it was more exaggerated than in Phase 1 since no saline controls had the ability
to initiate clot formation in INTEM, FIBTEM or APTEM tests (Table 4). Interestingly, sham
animals (no bleed) had a progressive hypocoagulopathy in Phase 2 but differed from phase 1
in that clot initiation and strength were both reduced (Table 4). Shams in Phase 1 showed pro-
longed clot times but could still form viable clots similar to baseline. A worsening hypocoagu-
lopathy in shams may reflect the combination of accidental hypothermia, anesthesia and long
ventilation times (see Discussion). In contrast, ALM-treated animals did better than shams
and all other groups after Phase 2 resuscitation, despite having slightly prolonged CT and
reduced clot strength.
Plasma fibrinogen levels. Baseline plasma fibrinogen level was 2.43 g/dL. After Phase 1,
values for shams, no-treatment, saline, ALM and Hextend1 groups were 1.37, 1.05, 0.97, 1.87
Table 3. ROTEM clot parameters for EXTEM, INTEM, FIBTEM, and APTEM tests after 60 min Phase 1 resuscitation.
Test Group Phase 1 Resuscitation Clot Initiation (%) CT (sec) α (˚) A10 (mm) MCF (mm) LI30 (%) ML (%)
EXTEM Baseline 100 40±1 83±0.3 70±1 74±1 100±0 6±0.5
Sham 75 214±155 83±0.7 68±3 60±11 100±0 2±1
No Treatment 38 162±89 60±21* 43±16# 46±15* 88±8 27±16‡
Saline Control 88 154±53 58±10# 38±9# 44±8* 96±3 5±3
ALM Therapy 100 46±3 83±0.2 68±1 71±0.5 100±0 3±0.5
Hextend® 63 281±113 57±12# 42±9# 49±6* 92±5 11±7
INTEM Baseline 100 92±5 85±0.2 73±0.5 76±0.5 100±0 6±1
Sham 50 462±299† 65±14† 52±13 67±4 100±0 3±1
No Treatment 38 458±146† 26±18* 21±14* 25±13# 99±1 6±6
Saline Control 75 349±227 46±11* 35±11* 45±10* 100±0 3±2
ALM Therapy 100 255±73† 79±3 66±2 72±1 100±0 2±0.5
Hextend® 38 680±251† 45±35† 23±17* 27±15# 86±15 20±20
FIBTEM Baseline 100 36±1 79±1 15±1 16±1 99±0.5 3±1
Sham 75 587±525† 72±2 12±1 13±1 99±1 3±1
No Treatment 25 86±30* 59 (n = 1) 10±2 12±2 100±0 0±0
Saline Control 75 325±162* 75 (n = 1) 6±2 6±2 100±0 1±0.5
ALM Therapy 100 45±2 75±1 12±1 13±1 98±1 5±1
Hextend® 50 400±218* 68 (n = 1) 7±2 9±2 100±0 0±0
APTEM Baseline 100 43±1 84±0.3 70±0.5 73±0.5 100±0 6±1
Sham 63 83±23 81±2 66±2 70±1 99±1 6±2
No Treatment 25 155±58 53±28* 37±25 41±22 79±21 26±26
Saline Control 75 236±103 63±13* 35±11# 39±12 96±4 9±4
ALM Therapy 100 51±2 83±0.3 67±1 70±1 100±0 5±1
Hextend® 63 388±163* 52±13# 39±10* 46±7 87±9 16±12
Data represent mean ± standard error of the mean. Clot initiation represents percentage of animals of n = 8 that initiated 2 mm clot formation. CT = clotting
time (sec); CFT = clot formation time (sec); α = alpha angle (˚); CFR = clot formation rate (˚); A10 = clot amplitude 10 min after clot initiation (mm);
MCF = maximum clot firmness (mm); LI30 = lysis index 30 min (%); ML = maximum lysis (%). Baseline values were obtained from 8 healthy anaesthetized,
ventilated rats with one femoral cut-down to obtain an arterial blood sample (see Methods).
*p<0.05 compared to Baseline and ALM;
#p<0.05 compared to Baseline, Sham, and ALM;
†p<0.05 compared to Baseline;
‡p<0.05 compared to Baseline, Sham, Saline controls, and ALM.
https://doi.org/10.1371/journal.pone.0188144.t003
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Table 4. ROTEM clot initiation and propagation parameters for EXTEM, INTEM, FIBTEM, and APTEM tests after Phase 2 resuscitation following
traumatic hemorrhage and shock.
Test Group Phase-2 Resuscitation Clot Initiation (%) CT (sec) α (˚) A10 (mm) MCF (mm) LI30 (%) ML (%)
EXTEM Baseline 100 40±1 83±0.3 70±1 74±1 100±0 6±1
(n = 8) (8/8)
Sham 50 175±13 80±3 46±1 52±1 100±0 0.5±0.5
(n = 8) (4/8) (n = 4) (n = 3) (n = 4) (n = 4) (n = 4) (n = 4)
No-Treatment 50 58±14† 82±2 65±4† 65±4† 76±25 48±44
(n = 4) (2/4) (n = 2) (n = 2) (n = 2) (n = 2) (n = 2) (n = 2)
Saline-Control 17 1519 7 6 17 100 0
(n = 6) (1/6) (n = 1) (n = 1) (n = 1) (n = 1) (n = 1) (n = 1)
ALM-Therapy 100 81±22† 78±3 58±3† 63±3† 87±6 18±9
(n = 8) (8/8)
Hextend® 50 55 82 62 65 100 0
(n = 2) (1/2) (n = 1) (n = 1) (n = 1) (n = 1) (n = 1) (n = 1)
INTEM Baseline 100 92±5 85±0.2 73±0.5 76±0.5 100±0 6±1
(n = 8) (8/8)
Sham 25 102±14 78±7 61±8 67±7 100±0 1±1
(n = 8) (2/8) (n = 2) (n = 2) (n = 2) (n = 2) (n = 2) (n = 2)
No-Treatment 50 113±6 82±2 69±1 72±4 87±13 17±15
(n = 4) (2/4) (n = 2) (n = 2) (n = 2) (n = 2) (n = 2) (n = 2)
Saline-Control 0 NA NA NA NA NA NA
(n = 6) (0/6)
ALM-Therapy 75 164±43 62±10† 46±8† 57±6† 88±10 18±14
(n = 8) (6/8) (n = 6) (n = 6) (n = 6) (n = 6) (n = 6) (n = 6)
Hextend® 0 NA NA NA NA NA NA
(n = 2) (0/2)
FIBTEM Baseline 100 36±0.6 79±1 15±0.5 16±1 99±0.5 3±1
(n = 8) (8/8)
Sham 38 43±7 77±1 13±1 14±1 100±0 3±3
(n = 8) (3/8) (n = 3) (n = 3) (n = 3) (n = 3) (n = 3) (n = 3)
No-Treatment 50 53±16 71±9 12±1† 13±0 100±0 0±0
(n = 4) (2/4) (n = 2) (n = 2) (n = 2) (n = 2) (n = 2) (n = 2)
Saline-Control 0 NA NA NA NA NA NA
(n = 6) (0/6)
ALM-Therapy 100 108±49† 70±5 10±1† 11±1† 99±1 1±1
(n = 8) (8/8)
Hextend® 50 55 76 12 13 100 0
(n = 2) (1/2) (n = 1) (n = 1) (n = 1) (n = 1) (n = 1) (n = 1)
APTEM Baseline 100 43±1 84±0.3 70±0.5 73±0.5 100±0 6±1
(n = 8) (8/8)
Sham 63 204±126 83±0.3 42±15 44±16 100±0 1±0.2
(n = 8) (5/8) (n = 5) (n = 3) (n = 5) (n = 5) (n = 5) (n = 5)
No-Treatment 50 61±18 83±1 61±77 68±4 76±25 32±29
(n = 4) (2/4) (n = 2) (n = 2) (n = 2) (n = 2) (n = 2) (n = 2)
Saline-Control 0 NA NA NA NA NA NA
(n = 6) (0/6)
ALM-Therapy 100 107±44 77±4 58±4 63±3 80±10 15±7
(n = 8) (8/8)
Hextend® 50 60 83 67 72 100 1
(n = 2) (1/2) (n = 1) (n = 1) (n = 1) (n = 1) (n = 1) (n = 1)
Data represent mean ± standard error of the mean. n = 8 except where indicated due to early mortality. NA = Not Applicable. Baseline values were obtained
from 8 healthy anaesthetized, ventilated rats with one femoral cut-down to obtain an arterial blood sample (see Methods). Clot initiation represents
percentage of animals that initiated 2 mm clot formation. CT = clotting time (sec); CFT = clot formation time (sec); α = alpha angle (˚); CFR = clot formation
rate (˚); A10 = clot amplitude 10 min after clot initiation (mm); MCF = maximum clot firmness (mm); LI30 = lysis index 30 min (%); ML = maximum lysis (%).
†p<0.05 compared to Baseline.
https://doi.org/10.1371/journal.pone.0188144.t004
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and 0.64 g/dL respectively, and after Phase 2 were 1.43, 1.86, 0.45, 1.39 and 0.75 g/dL respec-
tively (Fig 2).
Platelet aggregation. Platelet count in all groups increased by around 2.5 times at Phase 1
then stabilized during Phase 2 or at death (Fig 3A). Maximum ADP-stimulated platelet aggre-
gation for shams, no-treatment, saline controls, ALM and Hextend1 were 16%, 0.78%, 0.75%.
37.4% and 4% respectively (Fig 3B). The ALM group ADP-stimulated aggregation was signifi-
cantly higher than all groups except shams (Fig 3B). Maximum collagen-stimulated platelet
aggregation was 33%, 0.89%, 1.5%, 14% and 6% respectively (Fig 3C). ALM group collagen-
stimulated aggregation was significantly higher than all groups except shams.
Rectal temperature
Temperature in the ALM group was maintained throughout Phase 1 resuscitation and over
the first 2 hours of Phase 2 infusion, and then decreased by 1.5˚C (~34.6 to 33.1˚C) at 150 min,
before steadily decreasing to 31.3˚C at 300 min (Fig 4). Temperature in saline controls was sig-
nificantly lower and gradually decreased during Phase 1 from 34.1 to 33.6˚C, and this contin-
ued in Phase 2 until 150 min when it sharply increased by 1˚C, then fell to 30.5˚C at 300 min.
Sham temperature was 33.8˚C before Phase 1 and decreased to 32˚C at 300 min (Fig 4).
Discussion
Systemic inflammation and coagulopathy are major drivers of injury progression and depend
upon the type, severity and duration of tissue injury and hemorrhagic shock [1, 2, 12]. We
report that small-volume 3% NaCl ALM bolus and 0.9% NaCl ALM ’drip’ bolstered the host’s
defense against non-compressible traumatic bleeding by: 1) defending hematopoietic-immune
cell numbers, 2) blunting the systemic inflammatory response, 3) improving platelet function,
4) correcting coagulopathy, and defending body temperature. Saline controls were similar to
no-treatment; they were pro-inflammatory, had an activated immune system, lost their ability
to aggregate platelets, and were hypocoagulable. Hextend1 resuscitation led to the worst
outcomes.
ALM invoked an immune-bolstering defense against trauma and
hemorrhage
Phase 1 single-bolus resuscitation. Immune effector cells are in high demand following
traumatic hemorrhagic shock and can be rapidly taken-up by injured tissues to initiate healing
[27, 28]. After Phase 1, we showed that total white blood cells in saline controls significantly
fell by 30%, red cell count by 15%, hemoglobin and HCT by 12%, lymphocytes by ~50% and
neutrophils increased by ~200% compared to baseline (Table 1). In contrast, ALM-treated ani-
mals had total white and red cell counts similar to shams (9–15% losses) (Table 1). A most
interesting finding was that the ALM- and sham-groups had nearly identical percentage
changes in lymphocytes (40% decrease) and neutrophils (200% increase) as saline controls
(Table 1), indicating that this leukopenia-neutrophilia response was largely due to the stress or
trauma of surgery (laparotomy, surgical dissection and ventilation), since shams did not
undergo liver resection and hemorrhage.
Phase 2 ‘drip’ resuscitation. After Phase 2 (or at time of death), red cell counts, hemoglo-
bin and HCT in all non-ALM groups (except shams) continued to decrease (Table 1). How-
ever, total white cell numbers nearly doubled and this was associated with a 3-fold increase in
monocytes compared to baseline (Table 1). Lymphocyte numbers also rebounded to baseline
but neutrophil counts continued to increase in non-ALM groups (Table 1), which may be
associated with an end-stage inflammatory response (see below) associated with early
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Fig 3. Platelet count (109/L) (A) at baseline, after 60 min Phase 1 resuscitation, and 240 min and 300
min Phase 2 resuscitation, and ADP- (B) and collagen-induced (C) maximum platelet aggregation
after Phase 2 resuscitation in shams, no-treatment, saline, ALM, and Hextend® groups. Values
represent mean ± SEM. n = 8 for all groups. *p<0.05 compared to Sham and ALM groups; #p<0.05 compared
to ALM group.
https://doi.org/10.1371/journal.pone.0188144.g003
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mortality [29]. In contrast to Phase 1, these alterations in lymphocyte, neutrophil and mono-
cyte counts were a response to hemorrhagic shock, not the trauma of surgery. A standout
result throughout Phase 2 was that the ALM infusion group maintained their differential white
cell profile similar to shams (Table 1), implying that ALM mounted an immune-bolstering
defense against the ’sterile stressors’ of traumatic hemorrhagic shock.
ALM suppressed systemic inflammation: Possible role of the
inflammasome
Interestingly, the reciprocal changes of circulating lymphocyte and neutrophil counts after
Phase 1 were not predictive of the degree of systemic inflammation in any group. Saline con-
trols, no-treatment and Hextend1 group all developed an increased inflammatory response,
which worsened during Phase 2, whereas the ALM-treated animals showed little activation of
inflammation with plasma IL-1α and IL-1β levels being below the assay’s detection limits, and
IL-2, IL-6 and TNF-α below baseline values (Table 2). Similarly, after Phase 2, ALM treatment
led to plasma cytokines/chemokine levels that were less than or similar to shams. This suppres-
sion effect of ALM during Phase 2 is highlighted by saline controls having up to two orders of
magnitude higher IL-1α, IL-1β, IL-2, IL-6, RANTES and IFN-γ levels compared to Phase 1 or
baseline (Table 2). Moreover, ALM therapy blunted IL-6 production by ~90% (Table 2), and
supported previous findings in a rat model of surgical trauma (single laparotomy) showing
reduced IL-6 expression in ALM-treated animals compared with saline controls [30]. The dif-
ferences in systemic inflammation between ALM and saline-controls in this study most likely
reflect differences in the immune cell activation states, not cell numbers, because as stated ear-
lier each group had the same or similar percentage changes in circulating lymphocytes and
neutrophils after Phase 1. In conclusion, we showed that the ALM bolus/infusion appears to
Fig 4. Temperature (˚C) at baseline (Pre-bleed), and during Phase 1 and Phase 2 resuscitation in
shams, no-treatment animals, saline controls, ALM therapy group, and Hextend®-treated animals.
Values represent mean ± SEM. All values n = 8 except for groups with mortality. For No-Treatment group n7
from 30 min Phase 1; n = 0 from 150 min Phase 2. For Saline controls n6 from 45 min Phase 1. For
Hextend® group n7 from 15 min Phase 1 until 60 min Phase 2; n = 0 from 90 min Phase 2. †p<0.05
compared to all other groups.
https://doi.org/10.1371/journal.pone.0188144.g004
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have provided a permissive environment for healing without inflammation being overex-
pressed systemically.
While we did not study the underlying mechanisms, ALM therapy may have suppressed
systemic inflammation from: 1) blunting receptor recognition of damage-associated molecular
patterns (DAMPS) or ’alarmins’ that are located on surveillance cells [31–34], and/or 2) sup-
pressing the transition-to-activation of those signaling ’sensors’ by blunting the effector
responses [35–37]. Endogenous danger signals are largely detected by pattern-recognition
receptors (e.g. Toll-like receptors) located on resident and systemic immune cells, including
neutrophils, which in turn activate a cytosolic multiprotein complex known as the inflamma-
some [38, 39]. The inflammasome is an ’effector’ signaling platform that releases IL-1, which
triggers the induction and amplification of downstream inflammatory cascades to promote
healing. However, when IL-1 is overexpressed it can cause excessive inflammation and multi-
ple organ dysfunction [39, 40]. In partial support of ALM inhibition of inflammasome signal-
ing, we showed that IL-1β and IL-1α were undetected in plasma at Phase 1 compared to saline
controls (50 and 205 pg/ml respectively), and only increased to ~5% of control values after
Phase 2 (Table 2). ALM’s ability to blunt systemic inflammation parallels a separate study we
recently published in the rat model of polymicrobial sepsis, where we showed that a 0.9% NaCl
ALM saline ’drip’ administered for 4 hours (total volume 1.6 ml) led to little or no systemic
inflammation and 88% survivability after 6 days with no antibiotics [19].
ALM prevented coagulopathy and defended higher rectal temperatures
In addition to blunting systemic inflammation, ALM therapy corrected coagulopathy, a find-
ing that we have previously reported after pressure-controlled and volume-controlled hemor-
rhagic shock [11, 22, 23], cardiac arrest [21] and sepsis [15, 41]. In direct contrast, saline-
controls, no-treatment and Hextend1 animals all showed a worsening of hypocoagulopathy
(Fig 2, Tables 3 and 4), which was associated with significantly higher internal blood loss (over
2.5 times) and earlier death compared to the ALM group [29]. ALM correction of coagulopa-
thy was associated with a 1.9- and 3.1-fold higher plasma fibrinogen than controls, and a shift
towards baseline values, after Phase 1 and 2 respectively (Fig 2). In the Hextend1 group,
fibrinogen levels fell by 74% after Phase 1. In contrast to our previous pressure-controlled
hemorrhage model (~40% blood loss) with 60 min shock for saline-controls [22, 26], the pres-
ent model did not trigger hyperfibrinolysis, which may be due to the pressure-controlled
model having greater blood loss and prolonged hypoperfusion times leading to more extensive
endothelial damage and activation of the protein C and fibrinolytic pathways [11].
During Phase 1, ALM animals also regulated significantly higher body temperatures than
the other groups, which may reflect improved hypothalamic thermoregulatory balance from
up to 60% less blood loss from early correction of coagulopathy and improved cardiovascular
function [29]. After 2 hours into Phase 2, ALM rectal temperature fell by ~1.5˚C then slowly
decreased to 31.3˚C at 5 hours, but interestingly this had no effect on coagulation status. Falls
in body temperature in Phase 2 in ALM and other groups may also be associated with differ-
ences in blood loss, combined with anesthesia and long ventilation times [42–44].
ALM therapy improved platelet aggregation function
Differences in coagulopathy among the groups were also mirrored by differences in platelet
aggregation measurements. Platelets from ALM-treated animals showed a significant 50-fold
higher ADP-stimulated aggregation compared to saline controls and 9.3 times higher in colla-
gen-activated aggregation (Fig 4BC), whereas platelets in saline controls (and Hextend1 and
no-treatment groups) appeared to have lost their ability to aggregate, which likely contributed
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to their failure to form a viable clot in ROTEM tests (Fig 4BC). Higher ADP aggregation
responses from ALM-treated animals may reflect reduced collagen-linked release of alpha-
granules in vivo and reduced cytokine production of IL-1β and RANTES, which we found in
the ALM group (Table 2). This finding may be clinically significant because Kutcher and col-
leagues reported in 101 patients that 46% showed decreased platelet aggregation in response to
ADP, thrombin receptor-activating peptide, arachidonic acid, and/or collagen, and this defect
was associated with a 10-fold increase in mortality [45]. Solomon and colleagues also showed
similar results in 163 trauma patients between platelet aggregation defects, reduced clot
strength and increased mortality [46].
In addition to improving in vivo platelet function, ALM has recently been shown to confer
equivalency for in vitro storage of cold-stored platelets in platelet additive solution [47]. Inter-
estingly, improvements were shown in the aggregation response to collagen and thrombin
receptor activation peptide (TRAP6) by adenosine (A), magnesium (M), A + M and ALM
treatment, but not ADP enhancement [47]. In contrast, we found in vivo that there was a pre-
dominance of ADP enhancement of aggregation, not collagen, which may reflect different
mechanisms in vivo, and involve a functional endothelium. As with white cell differentials,
increases in platelet counts during Phase 1 in all groups, and stabilization in Phase 2 (Fig 3A)
were not predictive of differences in the ability to activate and aggregate. Similar increases
have been reported in humans following traumatic coagulopathy [48].
Potential clinical significance
One of the key outcomes of the present study was ALM’s small-volume capability (low-cube
weight) to blunt immune-inflammatory response to the trauma of surgery and non-compress-
ible blood loss and shock. A total of 0.945 ml was administered over 5 hours for a 350g rat
which, if translated, would equate to ~189 ml for a 70-kg human. This may be useful for mili-
tary medics in far-forward locations or first responders in urban and rural retrieval medicine,
who currently do not have many good options for treating non-compressible hemorrhage at
the point-of-injury or during evacuation. This may be particularly relevant when blood or
blood products are not readily available, or if they are available, may not be the safest option
[35, 49–51]. The ALM therapy may also have a role in damage control surgery.
Limitations of the present study
The present study has a number of strengths and limitations. A possible strength is that the
animal model allows the benefits and adverse events of new therapies to be examined in a con-
trolled manner from a ’systems’ approach. A major weakness is that whole body studies are
exceedingly complex and few animal studies translate into human use. In vivo studies are also
plagued with the difficulty of unravelling the underlying mechanisms to a particular challenge
and require in vitro systems. Another limitation is that our animals were anesthetized and pos-
itively ventilated for up to 6 hours, which may have affected the physiology of the system, as
was reflected in shams. Lastly, we did not examine immune cells in their different activated
states during Phases 1 and 2, such as T-cell effector functions and their natural killer subsets,
or macrophage M1/M2 phenotypes and neutrophil modulation in response to traumatic hem-
orrhagic shock.
Conclusions
Small-volume ALM therapy improved hematopoietic-immune function and attenuated
inflammation over 5 hours in the rat model of non-compressible traumatic hemorrhage.
Saline-controls were proinflammatory, progressively hypocoagulable and similar to no-
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treatment. Correction of coagulopathy in ALM-treated animals was associated with a signifi-
cant ADP- and collagen-stimulated platelet aggregation. Hextend1 treatment led to profound
inflammation and coagulopathy. ALM therapy appears to have acted like a host-directed
immune modulator following hemorrhagic shock and may have applications in the treatment
of traumatically injured patients to correct trauma-induced coagulopathy and prevent sys-
temic inflammatory response syndrome and progression to multiple organ failure.
Acknowledgments
The authors would like to thank USSOCOM and the College of Medicine and Dentistry,
James Cook University.
Author Contributions
Conceptualization: Hayley Letson, Geoffrey Dobson.
Data curation: Hayley Letson.
Formal analysis: Hayley Letson, Geoffrey Dobson.
Funding acquisition: Hayley Letson, Geoffrey Dobson.
Investigation: Hayley Letson, Geoffrey Dobson.
Methodology: Hayley Letson, Geoffrey Dobson.
Project administration: Hayley Letson, Geoffrey Dobson.
Resources: Geoffrey Dobson.
Supervision: Geoffrey Dobson.
Writing – original draft: Hayley Letson, Geoffrey Dobson.
Writing – review & editing: Hayley Letson, Geoffrey Dobson.
References
1. Stannard A, Morrison JJ, Scott DJ, Ivatury RA, Ross JD, Rasmussen TE. The epidemiology of noncom-
pressible torso hemorrhage in the wars in Iraq and Afghanistan. J Trauma Acute Care Surg 2013 74
(3):830–4. https://doi.org/10.1097/TA.0b013e31827a3704 PMID: 23425743
2. Kisat M, Morrison JJ, Hashmi ZG, Efron DT, Rasmussen TE, Haider AH. Epidemiology and outcomes
of non-compressible torso hemorrhage. J Surg Res. 2013; 184(1):414–21. https://doi.org/10.1016/j.jss.
2013.05.099 PMID: 23831230
3. Eastridge BJ, Mabry RL, Seguin P, Cantrell J, Tops T, Uribe P, et al. Death on the battlefield (2001–
2011): implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012; 73(6 Suppl
5):S431–7. https://doi.org/10.1097/TA.0b013e3182755dcc PMID: 23192066
4. Butler FK, Holcomb JB, Schreiber MA, Kotwal RS, Jenkins DA, Champion HR, et al. Fluid Resuscitation
for Hemorrhagic Shock in Tactical Combat Casualty Care: TCCC Guidelines Change 14–01–2 June
2014. J Spec Oper Med 2014; 14(3):13–28. PMID: 25344706
5. Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an overview of epidemiol-
ogy, clinical presentations, and therapeutic considerations. J Trauma. 2006; 60(6 (Suppl)):S3–11.
6. Maegele M. The coagulopathy of trauma. Eur J Trauma Emerg Surg 2014; 40:113–26. https://doi.org/
10.1007/s00068-014-0389-4 PMID: 26815891
7. Kashuk JL, Moore EE, Millikan JS, Moore JB. Major abdominal vascular trauma—a unified approach. J
Trauma. 1982; 22(8):672–9. PMID: 6980992
8. Mikhail J. The trauma triad of death: hypothermia, acidosis, and coagulopathy. AACN Clin Issues.
1999; 10(1):85–94. PMID: 10347389
9. Moore EE, Moore FA, Harken AH, Johnson JL, Ciesla D, Banerjee A. The two-event construct of postin-
jury multiple organ failure. Shock. 2005; 24(Suppl 1):71–4.
ALM therapy suppresses systemic inflammation
PLOS ONE | https://doi.org/10.1371/journal.pone.0188144 November 16, 2017 17 / 19
10. Brohi K. Trauma Induced Coagulopathy. JR Army Medical Corps. 2010 155(4):320–22.
11. Dobson GP, Letson HL, Sharma R, Sheppard F, Cap AP. Mechanisms of Early Traumatic-Induced
Coagulopathy (TIC): The Clot Thickens or Not? J Trauma Acute Care Surg. 2015; 79(2):301–9. https://
doi.org/10.1097/TA.0000000000000729 PMID: 26218701
12. Moore HB, Moore EE, Gonzalez E, Chapman MP, Chin TL, Silliman CC, et al. Hyperfibrinolysis, physio-
logic fibrinolysis, and fibrinolysis shutdown: The spectrum of postinjury fibrinolysis and relevance to anti-
fibrinolytic therapy. J Trauma Acute Care Surg. 2014; 77(6):811–7. https://doi.org/10.1097/TA.
0000000000000341 PMID: 25051384
13. Aird WC. Spatial and temporal dynamics of the endothelium. J Thromb Haemost. 2005; 3(7):1392–406.
https://doi.org/10.1111/j.1538-7836.2005.01328.x PMID: 15892866
14. Danese S, Dejana E, Fiocchi C. Immune Regulation by Microvascular Endothelial Cells: Directing
Innate and Adaptive Immunity, Coagulation, and Inflammation. J Immunol. 2007; 178:6017–22. PMID:
17475823
15. Dobson GP, Letson HL. Adenosine, Lidocaine and Mg2+ (ALM): From Cardiac Surgery to Combat
Casualty Care: Teaching Old Drugs New Tricks. J Trauma and Acute Care Surgery. 2016; 80(1):135–
45.
16. Dobson GP, Faggian G, Onorati F, Vinten-Johansen J. Hyperkalemic cardioplegia in adult and pediatric
cardiac surgery: end of an Era? Frontiers in Clinical and Translational Physiology. 2013; 4(Aug 28):1–
28.
17. Granfeldt A, Letson HL, Hyldebrandt JA, Wang ER, Salcedo PA, Nielson TK, et al. Small-Volume 7.5%
NaCl adenosine, lidocaine and Mg2+ has multiple benefits during hypotensive and blood resuscitation
in the pig following severe blood loss: Rat To Pig Translation. Critical Care Medicine. 2014; 42(5):e329–
e44. https://doi.org/10.1097/CCM.0000000000000225 PMID: 24557427
18. Granfeldt A, Letson HL, Dobson GP, Shi W, Vinten-Johansen J, Tønnesen E. Adenosine, lidocaine and
Mg2+ improves cardiac and pulmonary function, induces reversible hypotension and exerts anti-inflam-
matory effects in an endotoxemic porcine model. Crit Care 2015; 18 (6):682.
19. Griffin MJ, Letson HL, Dobson GP. Small-volume Adenosine, lidocaine and Mg2+ (ALM) 4 hour infusion
leads to 88% survival after 6 days of experimental sepsis in the rat without antibiotics. Clin Vaccine
Immunol. 2016; 23(11):863–72. https://doi.org/10.1128/CVI.00390-16 PMID: 27581435
20. Letson HL, Dobson GP. 3% NaCl adenosine, lidocaine, Mg2+ (ALM) bolus and 4 hours “drip” infusion
reduces noncompressible hemorrhage by 60% in a rat model. Journal of Trauma and Acute Care Sur-
gery. 2017; 82(6):1063–72. https://doi.org/10.1097/TA.0000000000001454 PMID: 28520687
21. Djabir Y, Letson HL, Dobson GP. Adenosine, lidocaine and Mg2+ (ALM) increases survival and corrects
coagulopathy after 8 min asphyxial cardiac arrest in the rat. Shock. 2013; 40(3):222–32. https://doi.org/
10.1097/SHK.0b013e3182a03566 PMID: 23846412
22. Letson HL, Dobson GP. Correction of Acute Traumatic Coagulopathy with small-volume 7.5% NaCl
Adenosine, Lidocaine and Mg2+ (ALM) occurs within 5 min: A ROTEM Analysis. J Trauma and Acute
Care Surgery. 2015; 78(4):773–83.
23. Letson HL, Pecheniuk NM, Mhango LP, Dobson GP. Reversal of Acute Coagulopathy during hypoten-
sive resuscitation using Small-Volume 7.5% NaCl with Adenocaine and Mg2+ in the Rat Model of
Severe Hemorrhagic Shock. Crit Care Med 2012; 40:2417–22. https://doi.org/10.1097/CCM.
0b013e31825334c3 PMID: 22809911
24. Letson HL, Dobson GP. Ultra-Small IV bolus of 7.5% NaCl/Mg2+ with adenosine and lidocaine (ALM)
improves early resuscitation outcome in the rat following severe hemorrhagic shock in vivo. J Trauma.
2011; 71(3):708–19. https://doi.org/10.1097/TA.0b013e3181fa27c7 PMID: 21248646
25. Messora MR, Nagata MJH, Furlaneto FAC, Dornelles RCM, Bomfim SRM, Deliberador TM, et al. A
standardized research protocol for platelet-rich plasma (PRP) preparation in rats. RSBO 2011; 8
(3):299–304.
26. Letson HL, Dobson GP. Differential contributions of platelets and fibrinogen to early coagulopathy in a
rat model of hemorrhagic shock. Thromb Res. 2016; 141(March):58–61.
27. Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early hematopoiesis in infection
and inflammation. Blood. 2012; 119(13):2991–3002. https://doi.org/10.1182/blood-2011-12-380113
PMID: 22246037
28. de Bruin AM, Voermans C, Nolte MA. Impact of interferon-g on hematopoiesis. Blood. 2014; 124
(16):2479–86. https://doi.org/10.1182/blood-2014-04-568451 PMID: 25185711
29. Letson HL, Dobson GP. 3.0% NaCl Adenosine, Lidocaine, Mg2+ (ALM) bolus and 4 hours ‘drip’ infusion
reduces non-compressible hemorrhage by 60% in a rat model. J Trauma Acute Care Surg. 2017; 82
(6):1063–72. https://doi.org/10.1097/TA.0000000000001454 PMID: 28520687
ALM therapy suppresses systemic inflammation
PLOS ONE | https://doi.org/10.1371/journal.pone.0188144 November 16, 2017 18 / 19
30. Davenport L, Letson HL, Dobson GP. Immune-inflammatory activation after a single laparotomy in a rat
model: effect of adenosine, lidocaine and Mg2+ infusion to dampen the stress response. Innate immu-
nity. 2017; 23(5):482–94. Epub 2017/07/12. https://doi.org/10.1177/1753425917718921 PMID:
28691873.
31. Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin
Crit Care. 2006; 12:595–601. https://doi.org/10.1097/MCC.0b013e3280106806 PMID: 17077693
32. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81
(1):1–5.
33. Hirsiger S, Simmen H-P, Werner CML, Wanner GA, Rittirsch D. Danger Signals Activating the Immune
Response after Trauma. Mediators of Inflammation. 2012; 2012(315941):1–10.
34. Martin SJ. Cell death and inflammation: the case for IL-1 family cytokines as the canonical DAMPs of
the immune system. FEBS J. 2016; 283(14):2599–615. https://doi.org/10.1111/febs.13775 PMID:
27273805
35. Stahel PF, Smith WR, Moore EE. Role of biological modifiers regulating the immune response after
trauma. Injury. 2007; 38:1409–22. https://doi.org/10.1016/j.injury.2007.09.023 PMID: 18048034
36. O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;
28:477–87. https://doi.org/10.1016/j.immuni.2008.03.002 PMID: 18400190
37. Stow JL, Muttay RZ. Intracellular trafficking and secretion of inflammatory cytokines. Cytokine & Growth
Factor Reviews 2013; 24:227–39.
38. Sollberger G, Strittmatter GE, Garstkiewicz M, Sand J, Beer H-D. Caspase-1: The inflammasome and
beyond. Innate Immunity. 2014; 20(2):115–25. https://doi.org/10.1177/1753425913484374 PMID:
23676582
39. Broz P, Dixit VD. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immu-
nol. 2016; 16(July):408–20.
40. Pittman K, Kubes P. Damage-associated molecular patterns control neutrophil recruitment. J Innate
Immun. 2013; 5(4):315–23. https://doi.org/10.1159/000347132 PMID: 23486162
41. Griffin MJ, Letson HL, Dobson GP. Adenosine, Lidocaine and Mg2+ (ALM) induces a reversible hypo-
tensive state, reduces lung edema and prevents coagulopathy in the rat model of polymicrobial sepsis.
J Trauma Acute Care Surg 2014; 77(3):471–8. https://doi.org/10.1097/TA.0000000000000361 PMID:
25159253
42. Kheirbek T, Kochanek AR, Alam HB. Hypothermia in bleeding trauma: a friend or a foe? Scand J
Trauma Resusc Emerg Med 2009; 17:65. https://doi.org/10.1186/1757-7241-17-65 PMID: 20030810
43. Lenhardt R. The effect of anesthesia on body temperature control. Front Biosci (Schol Ed). 2010; 2
(June 1):1145–54.
44. Søreide K. Clinical and translational aspects of hypothermia in major trauma patients: from pathophysi-
ology to prevention, prognosis and potential preservation. Injury 2014; 45(4):647–54. https://doi.org/10.
1016/j.injury.2012.12.027 PMID: 23352151
45. Kutcher ME, Redick BJ, McCreery BC, Crane IM, Greenberg MD, Cachola LM, et al. Characterization
of platelet dysfunction after trauma. J Trauma Acute Care Surg 2012; 73(1):13–9. https://doi.org/10.
1097/TA.0b013e318256deab PMID: 22743367
46. Solomon C, Traintinger S, Ziegler B, Hanke A, Rahe-Meyer N, Voelckel W, et al. Platelet function follow-
ing trauma. A multiple electrode aggregometry study. Thromb Haemost. 2011; 106(2):322–30. https://
doi.org/10.1160/TH11-03-0175 PMID: 21655681
47. Bynum JA, Taylor AS, Peltier GC, McIntrosh CS, Meledeo MA, Dobson GP, et al. Evaluation of Adeno-
sine, Lidocaine and Magnesiumfor Enhancement of Platelet Function During Storage. J Trauma Acute
Care Surg. 2017; XX: In press.
48. White NJ. Mechanisms of trauma-induced coagulopathy. Hematology Am Soc Hematol Educ Program.
2013; 2013:660–3. https://doi.org/10.1182/asheducation-2013.1.660 PMID: 24319248
49. Molina PE. Neurobiology of the stress response: contribution of the sympathetic nervous system to the
neuroimmune axis in traumatic injury. Shock. 2005; 24(1):3–10. PMID: 15988314
50. Groeneveld KM, Leenen LP, Koenderman L, Kesecioglu J. Immunotherapy after trauma: timing is
essential. Curr Opin Anaesthesiol. 2011; 24(2):219–23. https://doi.org/10.1097/ACO.
0b013e32834401e0 PMID: 21293264
51. Jackman RP. Immunomodulation in transfused trauma patients. Curr Opin Anaesthesiol. 2013; 26
(2):196–203. https://doi.org/10.1097/ACO.0b013e32835d7160 PMID: 23303513
ALM therapy suppresses systemic inflammation
PLOS ONE | https://doi.org/10.1371/journal.pone.0188144 November 16, 2017 19 / 19
